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of neutrophil engraftment, deﬁned as achieving and ANC of
500/L with 90% donor chimerism by day42 was 79% (95% CI
69-88%) and platelet engraftment, deﬁned as achieving an untrans-
fused count of 50,000/L by day 180 was 71% (95% CI 51-
74%). The cumulative incidence of Grade II-IV acute GvHD by
day 100 was 44% (95% CI 32-56%) and chronic GvHD by 1
year 23% (95% CI 8-27%). The cumulative incidence of overall
survival was 80% (95% CI 71-90%) and 72% (95% CI 61-83%) at
180 and 365 days, respectively. Recipient race, favoring Caucasian
[p  0.02], was the only parameter that impacted survival. HLA
matching by low or high resolution criteria did not impact survival.
Improved growth and cognitive function was seen in patients with
Hurler Syndrome and neonates transplanted with Krabbe disease.
Patients with presymptomatic ALD and juvenile MLD also did
well. Engraftment of donor cells was documented in heart and
brain in two patients studied at autopsy. In conclusion, unrelated
cord blood (UCB) represents an excellent stem cell source for
transplantation therapy for infants and young children with selec-
tive inborn errors of metabolism. UCB donors are readily available
and cord blood units generally contain more than sufﬁcient cell
doses for these younger and smaller patients. Newborn screening
for lysosomal and peroxisomal storage diseases would allow for
early diagnosis and maximally effective treatment.
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CORD BLOOD TRANSPLANTATION FOR CHILDREN WITH ACUTE LEU-
KEMIA: AN EUROCORD REGISTRY ANALYSIS
Gluckman, E. Hematology-Bone Marrow Transplant Department and
Eurocord ofﬁce, Hospital Saint Louis, Paris, France
Unrelated cord blood transplantation has been used to treat
patients with malignant and non-malignant hematopoietic disor-
ders for whom a HLA-compatible hematopoietic stem cell donor is
not available. The establishment of cord blood banks worldwide,
the increased number of cord blood units frozen and the shorter
time to ﬁnd a donor have made possible to use this source of
hematopoietic stem cells to treat more than 2 500 patients. The
Eurocord registry was established to study the clinical results of
cord blood transplantation and to compare the outcomes of unre-
lated transplants using either cord blood or bone marrow. Brieﬂy,
we have found in two distinct retrospective analyses concerning
children or adults with acute leukemia given either an unrelated
cord blood or bone marrow transplant, that leukemia free-survival
and relapse were similar in both types of graft (with adjustment for
confounding clinical factors). Cord blood recipients experienced
decreased incidence of acute graft-versus-host disease and delayed
hematopoietic recovery compared to bone marrow recipients. In
order to improve the delayed hematopoietic recovery after cord
blood transplantation, certain approaches have been investigated
such as ex-vivo expansion of cord blood cells, double cord blood
transplantation and reduced intensity conditioning regimen. We
have also attempted to establish some guidelines for cord blood
donor choice based on cord blood cell dose and number of HLA
disparities that have been found to be associated with hematopoi-
etic recovery.
Results of unrelated cord blood transplantation (UCBT) in
childhood acute myeloid leukemia: We analyzed 95 children
receiving UCBT for AML (20 in CR1, 47 in CR2 and 28 in more
advanced stage). Poor prognosis cytogenetic abnormalities were
identiﬁed in 29 cases. Most patients received a 1 or 2 HLA antigens
mismatched transplant. The median number of collected nucleated
cells (NC) was 5.2  107/kg. Cumulative incidence (CI) of neu-
trophil recovery was 78  4%, acute graft versus host disease
(GvHD) was 35  5% and 100-day transplant-related mortality
(TRM) was 20  4%. In multivariable analysis, a collected NC
dose higher than 5.2  107/kg was associated with a lower 100-day
TRM. The 2-year CI of relapse was 29  5% and was associated
with disease status. The 2-year LFS was 42  5%, (59  11% in
CR1, 50  8% in CR2, and 21  9% for children not in CR).
Children with poor prognosis cytogenetic features had similar LFS
compared to other patients (44  11% vs 40  8%). In CR2, LFS
was not inﬂuenced by the length of CR1 (53  11% in CR1 9.5
months compared to 50  12% in later relapses). We conclude
that UCBT is a good therapeutic for children with very poor
prognosis AML and who lack an HLA-identical sibling.
Results of unrelated cord blood transplant in children with
acute lymphoid leukemia: 195 patients with ALL were analyzed.
The median age at diagnosis was 4 years and at transplant 7 years.
The median follow-up time was 31 months. 35 patients were
transplanted in CR1 (with high risk cytogenetics abnormalities
85%), 85 in CR2, 45 in CR3 and 40 in relapse. 16 patients had
received a previous autologous or allogeneic transplant. The me-
dian number of nucleated cells infused was 3.8  107/kg, and the
median CD34 cell dose was 1.7  105/kg. The donor was HLA
identical in 21 cases, had 1/6 HLA differences in 80 cases, 2/6 HLA
differences in 78 cases and 3/6 HLA differences in 8 cases. Median
day to neutrophil engraftment was 29 days, median day to platelet
engraftment was 77 days. The cumulative incidence of neutrophil
engraftment at 60 days was 85%. It was dependent on the number
of nucleated cells infused. The incidence of GVH was low with
63% grade 0-1, 16% grade II, 12% grade III and 9% grade IV.
Estimate incidence of chronic GVH was 34%. Two-year trans-
plant related mortality was 39% in patients transplanted in CR and
58% in patients transplanted in relapse. In multivariate analysis, 3
factors were associated with an increasing probability of non-
leukemic death: advanced disease (p 0.04), previous transplant (p
 0.03) and centers performing less than 10 cord blood transplants
(p  0.0004). The cumulative incidence of relapse was 28%. The
predictive factors for relapse were: use of methotrexate for preven-
tion of GVH (p  0.02), longer time between diagnosis and CBT
(p  0.009), absence of acute GVH (p  0.002). Two-year DFS
was 36% in patients transplanted in CR and 15% in patients
transplanted in remission. Predictive factors increasing the proba-
bility of disease free survival were: remission status of the disease at
transplant (p  0.0006), previous transplant (p  0.0001), centers
performing less than 10 CBT (p  0.01). In conclusion, these
results show that unrelated HLA mismatched cord blood trans-
plant can cure a proportion of children with ALL who do not have
a bone marrow donor. The number of cells infused is a major
factor associated with hematopoietic recovery. The presence of
GVH is associated with a decreased risk of relapse. The center
effect is an important factor for survival probably in relation to the
selection of the patients (time to transplant) and donor choice
(number of cells infused).
Results of unrelated cord blood transplants compared to
unrelated bone marrow transplants in children with acute
leukemia: A multicenter retrospective analysis comparing the out-
come of unrelated cord blood transplant to unrelated bone marrow
transplants in children with acute leukemia was performed by
Eurocord and EBMT. Five hundred and ﬁfteen children with acute
leukemia receiving either an unrelated cord blood transplant
(UCBT, n  99) or an unrelated BMT (n  416) were analyzed.
Recipients of UCB were younger and had more pre-transplant
adverse disease factors. Most of the bone marrow donors were
HLA matched or had a maximum of 1 HLA difference while most
of the cord blood donors had 2 to 3 HLA differences. The median
number of nucleated cells infused was 4  108/kg in unrelated
BMT and 0.38  108/kg in unrelated UCBT. In unrelated BMT,
262 children received an unmanipulated BMT and 180 a T-cell
depleted BMT using Campath-1M as the most frequent means of
T-cell depletion. The median follow-up was 29 months. During
the ﬁrst 100 days after transplant, while unmanipulated and T-cell
depleted BMT did not differ in hematopoietic recovery and treat-
ment related mortality, the main ﬁndings that emerged from these
retrospective adjusted comparisons were the poor results of UCBT
concerning neutrophil and platelet recoveries and early transplant
related mortality. In contrast UCBT and T-cell depleted BMT
gave less acute GVHD than the unmanipulated BMT group. Fi-
nally the unmanipulated BMT and the UCBT groups had less
leukemic relapse than the T-cell depleted group. Considering the
long-term outcome, the unmanipulated BMT group had more
chronic GVHD than the T-cell depleted BMT and the UCBT
groups. Furthermore, while outcome in the 3 groups was compa-
rable in terms of long term relapse, mortality after day 100 was
increased in the T-cell depleted BMT group mostly because of the
occurrence during the ﬁrst 100 days post-BMT of early relapse and
infections. In summary, the main differences in adjusted outcomes
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between the three transplant groups appeared in the ﬁrst 100 days
post transplant but without giving advantage to any group. Indeed,
the delay of engraftment and increased treatment-related mortality
observed after UCBT must be balanced with the higher risk of
acute GVHD after unmanipulated BMT and with the higher risk
of relapse after T-cell depleted BMT. In contrast, after day 100
posttransplant, the 3 groups achieved similar results in terms of
relapse but chronic GVHD and death occurred more frequently
with unmanipulated BMT and T-cell depleted BMT respectively.
These results justify the simultaneous search for unrelated cord
blood and unrelated bone marrow donors for children with acute
leukemia. The decision to perform cord blood transplants will be
based on the cell content of the graft, the number of HLA dispar-
ities and the urgency of the transplant.
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UNRELATED CORD BLOOD TRANSPLANTATION FOR TRANSFUSION-
DEPENDENT THALASSEMIA IN CHILDREN
Jaing, T.H., Hung, I.J., Yang, C.P. Chang Gung Children’s Hospital,
Chang Gung University, Taoyuan, Taiwan
Hematopoietic stem cell transplantation is currently the only
curative therapy for transfusion-dependent thalassemia. However,
approximately 30% of patients have unaffected HLA-identical sib-
lings to serve as donors. We investigated the feasibility of unrelated
cord blood transplantation (CBT) as a potential strategy for aug-
menting the pool of acceptable donors. Between October 2003 and
December 2004, 9 children with 	-thalassemia major received
CBT with at least 2.5  107/kg TNC from unrelated donors (0-2
of 6 HLA antigens were mismatched) and were then evaluated for
engraftment, adverse effects, and treatment outcome. Condition-
ing consisted of busulfan, cyclophosphamide, and antithymocyte
globulin, and GVHD prophylaxis of cyclosporine and methylpred-
nisolone. Median age was 3.7 years (range, 2.3-11.4 years). One
patient died of penicillin-resistant S. mitis sepsis at day 8 prior to
the “expected” time to respond. Eight of 9 patients were alive at
median follow-up of 254 days after transplantation, with complete
donor chimerism and transfusion independence. The median times
to neutrophil engraftment, RBC transfusion independence, and
platelet engraftment were 13, 34, and 45 days after transplantation,
respectively. The patients showed grade I-III acute GVHD. No
extensive chronic GVHD had developed at the latest contact. The
medical costs per-patient with CBT in Taiwan is estimated to be
approximately US$40,000 plus the cost of the cord blood unit. In
summary, our results suggest that unrelated CBT is an alternative
treatment for patients with transfusion-dependent thalassemia
lacking an HLA-matched sibling bone marrow donor, and it is
clearly cost-effective when compared to conventional treatment
with blood transfusions and iron chelation therapy.
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OUTCOMES OF UNRELATED CORD BLOOD TRANSPLANTS AND ALLO-
GENEIC RELATED HEMATOPOIETIC STEM CELL TRANSPLANTS IN CHIL-
DREN WITH HIGH-RISK ACUTE LYMPHOCYTIC LEUKEMIA
Jacobsohn, D.A., Hewlett, B., Seshadri, R., Ranalli, M., Duerst, R.,
Kletzel, M. Children’s Memorial Hospital and Feinberg School of Med-
icine, Northwestern University, Chicago, IL
Background: HSCT is commonly used for pediatric ALL pa-
tients (pts) with early relapse or other high-risk features. Given
lack of matched-sibling donors and multiple advantages of UCB as
stem cell source (less GVHD, rapid availability), we compared
outcomes of pediatric ALL pts that underwent HSCT with UCB
(4-5/6 HLA) or matched-sibling transplant (6/6 HLA).
Methods: Pts included: ALL CR2 pts who relapsed 36 mos
from diagnosis and ALL CR1 pts with 1 high-risk feature (un-
favorable karyotype, poor response to induction, age 1 yr, WBC
100,000 at diagnosis). 25% of CR1 pts in both groups had 2
high-risk features. Cytoreduction (same in both groups): Pts re-
ceived TBI 150 cGy  8 (d 
10 to 
7); VP-16 1 g/m2/day (d 
6
to 
5); cyclophosphamide 60 mg/kg/day (d 
4 to 
2). GVHD
prophylaxis: CSA, short-course MTX, and ATG d1,3,5,7
(for UCB). Grafts were not T-cell depleted.
Results: There were 23 matched-sibling (20 BM/3 PBSC) and
26 UCB recipients. Both groups had equivalent high-risk factors.
Engraftment took longer in UCB recipients. TRM and GVHD
were equal in both groups. 3 yr EFS is 60% in both groups. Age,
gender, degree of HLA-matching for UCB, acute/chronic GVHD
did not affect EFS.
Conclusions: In pediatric pts with high-risk ALL in need of
HSCT, outcome of matched-sibling HSCT and UCB transplant is
equivalent with regards to TRM, GVHD, and EFS. UCB should
be considered a standard stem cell source to use in this group when
a matched sibling is not available.
Table 1.
Matched-sibling
(n  23) UCB (n  26) p
Age diagnosis
(yrs)* 2.5 (0.3-15.4) 3.9 (0.3-11.9) 0.63
Status at
HSCT (CR1) 11 (47.8%) 10 (38.5%) 0.34
Age <1 yr 7 (30.4%) 6 (23.1%) 0.56
Karyotype
(unfavorable) 8 (34.8%) 11 (42.3%) 0.79
Neutrophil
recovery (d)* 16 (13-21) 29 (21-35) <0.001
Platelet
recovery (d)* 24 (17-35) 51 (32-59) 0.011
100d TRM† 3 [13% (3-34)] 5 [19% (7-39)] 0.71
aGVHD (2-4)† 5 [22% (7-44)] 5 [19% (7-39)] 0.83
CGVHD (in at
risk)† 8 [40% (19-64)] 7 [33% (15-57)] 0.66
Relapse at 3
yrs† 5 [22% (7-44)] 4 [15% (4-35)] 0.72
3 yr EFS† 60% (40-80) 61% (42-80) 0.72
*Median (range); †% (95% CI).
24
TOTAL BODY IRRADIATION, FLUDARABINE, MELPHALAN AND ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR AD-
VANCED PEDIATRIC HEMATOLOGIC MALIGNANCIES
Petropoulos, D. M.D. Anderson Cancer Center, Houston, TX
The Fludarabine (F)-Melphalan (M) reduced-intensity prepara-
tive regimen has been successfully used in adults for allogeneic
hematopoietic stem cell transplant (HSCT). We evaluated the
efﬁcacy and toxicity of adding 9 Gy of total body irradiation (TBI),
in three single daily fractions of 3 Gy, to the reduced intensity
regimen of ﬂudarabine 30 mg/m2 i.v.  4 days and melphalan 140
mg/m2 i.v.  1 day in advanced pediatric hematologic malignan-
cies. GVHD prophylaxis consisted of tacrolimus and mini-meth-
otrexate. No anti-thymocyte globulin was used. Twenty-two acute
lymphoblastic leukemia (ALL), 6 acute myeloid leukemia (AML),
and 1 anaplastic large-cell lymphoma patients were transplanted.
Thirteen of these were beyond second remission, and ﬁve had prior
HSCT. Twenty-one donors were unrelated: 1-2 antigen mis-
matched cord blood (CB) for 19 patients, bone marrow in one and
peripheral blood stem cells (PBSC) in one. Three of the 8 related
donors were genotypically disparate. Oral mucositis and diarrhea
were the most common side effects seen. Twenty-seven patients
achieved neutrophil engraftment at a median of 16 days (range
11-35), and 23 had platelet engraftment (median 42 days, range
14-200). One patient had primary graft failure. Seven patients (all
with ALL) died of non-relapse causes in the ﬁrst 100 days. Six of 27
evaluable patients developed grade III-IV acute GVHD and three
chronic GVHD. Nine patients (7 with ALL) relapsed at a median
of 8 months post-transplant (range 2-54). With a median follow-up
of 55 (range 25-88) months, 7 of 22 ALL, 5 of 6 AML, 1 of 1
lymphoma patients are alive and in remission. This includes eight
of the 19 CBT recipients. The regimen of TBI, F and M allows the
engraftment of allogeneic HSC (including mismatched unrelated
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